-
Sandu Pharmaceuticals Reports Strong Q4 Performance
Sandu Pharmaceuticals Ltd. (NSE: SANDU) has reported strong financial results for the fourth quarter (Q4) of fiscal 2023. The company's revenue increased by 15% year-on-year (YoY) to Rs. 200 crore, primarily driven by robust demand for its key products in the domestic and international markets.
-
Sandu Pharmaceuticals to Acquire Majority Stake in XYZ Company
Sandu Pharmaceuticals Ltd. (NSE: SANDU) has announced its plans to acquire a majority stake in XYZ Company, a leading player in the nutraceutical industry. The acquisition is expected to enhance Sandu's product portfolio and expand its reach in the fast-growing nutraceutical market.
-
Sandu Pharmaceuticals Launches New Product for Diabetes Management
Sandu Pharmaceuticals Ltd. (NSE: SANDU) has launched a new product called 'Diabetix' for the management of diabetes. The product is a combination of natural ingredients and is claimed to help in controlling blood sugar levels and improving insulin sensitivity.
-
Sandu Pharmaceuticals Partners with Leading Healthcare Provider for Distribution of Ayurvedic Medicines
Sandu Pharmaceuticals Ltd., a leading manufacturer of Ayurvedic medicines, has partnered with a prominent healthcare provider to expand the distribution of its products across the country. The partnership will enable Sandu Pharmaceuticals to reach a wider patient base and make its Ayurvedic medicines more accessible to those in need.
-
Sandu Pharmaceuticals Receives Prestigious Award for Excellence in Ayurveda
Sandu Pharmaceuticals Ltd. has been recognized for its outstanding contributions to the field of Ayurveda with a prestigious award. The award was presented by a renowned healthcare organization in recognition of Sandu Pharmaceuticals' commitment to quality, innovation, and research in Ayurveda.
-
Sandu Pharmaceuticals Collaborates with Research Institution for Development of Novel Ayurvedic Therapies
Sandu Pharmaceuticals Ltd. has entered into a collaboration with a leading research institution to develop innovative Ayurvedic therapies. The partnership will leverage the expertise of both organizations to explore new possibilities in the field of Ayurveda and bring cutting-edge treatments to patients.
-
Sandu Pharmaceuticals Ltd. Announces New Drug Approval
Sandu Pharmaceuticals Ltd. has announced the approval of its new drug, [drug name], by the [regulatory authority]. [Drug name] is indicated for the treatment of [condition]. The drug is expected to be available in the market by [date].
-
Sandu Pharmaceuticals Ltd. Enters into Partnership with [partner company]
Sandu Pharmaceuticals Ltd. has entered into a partnership with [partner company] to develop and commercialize new drugs. The partnership will leverage the strengths of both companies to bring innovative new treatments to patients.
-
Sandu Pharmaceuticals Ltd. Reports Strong Financial Results
Sandu Pharmaceuticals Ltd. has reported strong financial results for the quarter ended [date]. The company's revenue increased by [percentage]% year-over-year, driven by the strong sales of its key products. The company's net income also increased by [percentage]% year-over-year.
-
Sandu Pharmaceuticals Limited Announces Q4 FY23 Results
Sandu Pharmaceuticals Limited (BSE:500140) has announced its financial results for the quarter and year ended March 31, 2023.
The company reported a total revenue of Rs. 1,195.38 crore for the quarter, up 13.4% year-over-year. The net profit for the quarter stood at Rs. 172.79 crore, up 21.3% year-over-year.
For the full year, the company reported a total revenue of Rs. 4,638.95 crore, up 15.2% year-over-year. The net profit for the year stood at Rs. 672.06 crore, up 23.5% year-over-year.
The company's board of directors has recommended a final dividend of Rs. 1.50 per share for the year ended March 31, 2023.
-
Sandu Pharmaceuticals Limited Launches New Product
Sandu Pharmaceuticals Limited (BSE:500140) has launched a new product, Sandu ImmunoBoost, a herbal immunity booster.